VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
REGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
REGNRegeneron Pharmaceuticals, Inc.
$945.53$97.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksREGNQuarterly Financials

Regeneron Pharmaceuticals, Inc. (REGN) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Regeneron Pharmaceuticals, Inc. (REGN) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

REGN Income Statement

Quarterly statement

REGN Income Statement

Regeneron Pharmaceuticals, Inc. (REGN) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21
Sales/Revenue5.12B4.29B3.61B3.88B3.75B3.68B3.03B3.79B3.72B3.55B3.15B3.43B3.36B3.16B3.16B3.41B2.94B2.86B2.97B4.95B
Revenue Growth %36.27%16.73%19.04%2.51%0.9%3.62%-3.7%10.33%10.65%12.32%-0.54%0.58%14.53%10.53%6.64%-31.05%-14.96%-44.4%17.26%104.37%
Cost of Goods Sold573.6M576.5M669.4M584.6M521.6M530.2M464.3M565.4M491.1M480.2M433.8M629.1M541.8M508M557M507M410.4M371.5M479.2M1.06B
COGS % of Revenue11.21%13.44%18.57%15.05%13.89%14.42%15.33%14.92%13.2%13.54%13.79%18.32%16.11%16.09%17.61%14.85%13.98%13%16.16%21.35%
Gross Profit4.54B3.71B2.94B3.3B3.23B3.15B2.56B3.22B3.23B3.07B2.71B2.81B2.82B2.65B2.61B2.91B2.53B2.49B2.49B3.89B
Gross Margin %88.79%86.56%81.43%84.95%86.11%85.58%84.67%85.08%86.8%86.46%86.21%81.68%83.89%83.91%82.39%85.15%86.02%87%83.84%78.65%
Gross Profit Growth %40.51%18.08%14.49%2.35%0.1%2.56%-5.41%14.92%14.49%15.73%4.07%-3.52%11.68%6.61%4.79%-25.35%-13.69%-43.17%15.45%93.94%
Operating Expenses2.49B2.29B2.29B2.42B2.21B2.07B1.97B2.23B2.05B2B1.96B1.75B1.61B1.63B1.6B1.59B1.3B1.18B1.2B1.25B
OpEx % of Revenue48.75%53.46%63.6%62.3%58.76%56.21%65.13%58.95%55.1%56.31%62.31%51.09%47.88%51.73%50.67%46.63%44.35%41.26%40.45%25.34%
Selling, General & Admin677.8M662.1M647.7M775M657.8M634.2M633M792.2M714.4M758.8M689M704.4M640.5M652M601.1M657M529.1M476.3M450M559.6M
SG&A % of Revenue13.25%15.43%17.96%19.95%17.52%17.25%20.9%20.91%19.2%21.39%21.91%20.51%19.05%20.65%19.01%19.24%18.02%16.67%15.18%11.3%
Research & Development1.82B1.63B1.65B1.63B1.56B1.43B1.34B1.43B1.33B1.22B1.26B1.05B969.9M982.2M1B941.6M818.7M719.9M769.5M711.1M
R&D % of Revenue35.5%38.03%45.64%41.86%41.5%38.95%44.23%37.63%35.68%34.5%39.92%30.59%28.84%31.1%31.68%27.58%27.88%25.2%25.95%14.36%
Other Operating Expenses0001000K-1000K001000K1000K1000K1000K-500K-500K-600K-500K-1000K-1000K-1000K-1000K-1000K
Operating Income2.05B1.42B642.9M879.9M1.03B1.08B591.7M990.2M1.18B1.07B751.4M1.05B1.21B1.02B1B1.32B1.22B1.31B1.29B2.64B
Operating Margin %40.04%33.11%17.83%22.65%27.35%29.37%19.54%26.13%31.7%30.15%23.89%30.59%36.01%32.19%31.71%38.53%41.68%45.74%43.39%53.31%
Operating Income Growth %99.47%31.59%8.65%-11.14%-12.95%0.93%-21.25%-5.76%-2.6%5.22%-25.07%-20.12%-1.04%-22.22%-22.06%-50.17%-33.75%-60.96%15.63%126.2%
EBITDA2.17B1.54B766.1M1.02B1.16B1.21B718.6M1.12B1.3B1.19B865.5M1.16B1.32B1.12B1.1B1.42B1.32B1.38B1.36B2.71B
EBITDA Margin %42.4%35.99%21.25%26.39%30.99%33.04%23.73%29.47%34.97%33.56%27.52%33.88%39.15%35.45%34.86%41.46%44.83%48.34%45.9%54.81%
EBITDA Growth %86.44%27.14%6.61%-8.21%-10.58%2.04%-16.97%-4.05%-1.15%6.31%-21.48%-17.79%0.01%-18.95%-19%-47.85%-31.46%-59.59%15.32%120.9%
D&A (Non-Cash Add-back)121M123.7M123.2M145M136.7M135.1M126.9M126.4M121.7M120.7M114.1M113M105.4M103.1M99.5M100.1M92.6M74.4M74.3M74.5M
EBIT2.29B1.54B844.1M1.06B1.78B1.52B913.7M968.6M1.51B1.64B716.8M1.17B1.13B1.1B876M1.34B1.53B976.3M1.07B2.52B
Net Interest Income171.2M172.3M170.6M181.1M155.8M171.2M164.8M172.6M173.6M164.6M145.4M130.4M115.9M99.4M-18M-17.4M-15.3M-13.1M-13.6M-14.1M
Interest Income181.8M183.3M183.5M193.3M175.1M174.8M173.5M183.1M187.4M179.4M161.5M148.7M133.7M118.3M000000
Interest Expense10.6M11M12.9M12.2M19.3M3.6M8.7M10.5M13.8M14.8M16.1M18.3M17.8M18.9M18M17.4M15.3M13.1M13.6M14.1M
Other Income/Expense235.9M107.3M188.3M163.8M736.5M439.2M313.3M-32.1M313.5M558.5M-50.7M96.9M-100.2M66.4M-144.8M9.3M286.1M-343.7M-225.5M-136.3M
Pretax Income2.28B1.53B831.2M1.04B1.76B1.52B905M958.1M1.49B1.63B700.7M1.15B1.11B1.08B858M1.32B1.51B963.2M1.06B2.5B
Pretax Margin %44.65%35.61%23.05%26.87%46.97%41.32%29.88%25.29%40.13%45.9%22.28%33.42%33.03%34.29%27.13%38.8%51.42%33.71%35.79%50.56%
Income Tax335.4M230.9M104M199.1M303.3M127.1M96.3M40.4M152.4M195.8M-21.3M-12M103M114.5M40.2M127.6M194.1M111.1M87.6M274.4M
Effective Tax Rate %14.68%15.11%12.51%19.08%17.2%8.37%10.64%4.22%10.21%12.03%-3.04%-1.05%9.27%10.57%4.69%9.63%12.86%11.53%8.26%10.96%
Net Income1.95B1.3B727.2M844.6M1.46B1.39B808.7M917.7M1.34B1.43B722M1.16B1.01B968.4M817.8M1.2B1.32B852.1M973.5M2.23B
Net Margin %38.09%30.23%20.17%21.74%38.89%37.86%26.7%24.22%36.03%40.38%22.96%33.77%29.97%30.66%25.86%35.06%44.81%29.82%32.83%45.01%
Net Income Growth %33.47%-6.81%-10.08%-7.97%8.91%-2.84%12.01%-20.86%33.02%47.9%-11.71%-3.13%-23.4%13.65%-15.99%-46.29%-19.39%-72.5%-12.71%93.96%
Net Income (Continuing)1.95B1.3B727.2M844.6M1.46B1.39B808.7M917.7M1.34B1.43B722M1.16B1.01B968.4M817.8M1.2B1.32B852.1M973.5M2.23B
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)18.4512.206.757.8613.6212.817.278.0611.5412.416.2710.198.898.507.1710.5011.667.478.6119.69
EPS Growth %35.46%-4.76%-7.15%-2.48%18.02%3.22%15.95%-20.9%29.81%46%-12.55%-2.95%-23.76%13.79%-16.72%-46.67%-18.63%-73.29%-14.67%92.29%
EPS (Basic)19.1612.596.998.2114.0913.247.588.5312.4013.256.7010.889.489.057.6411.1911.667.478.6120.99
Diluted Shares Outstanding105.6M106.8M107.7M107.5M107.2M108.6M111.2M113.8M116.2M115.4M115.1M113.8M113.4M113.9M114M114M112.8M114M113.1M113.2M
Basic Shares Outstanding101.7M103.4M104M102.9M103.62M105.1M106.7M107.9M108.1M108.1M107.8M106.6M106.3M107M107.1M107M112.8M114M113.07M106.2M
Dividend Payout Ratio4.91%7.46%13.45%10.98%6.25%6.65%11.6%-------------